X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6086) 6086
Book Review (312) 312
Publication (199) 199
Book Chapter (19) 19
Conference Proceeding (8) 8
Newsletter (3) 3
Book / eBook (2) 2
Dissertation (2) 2
Web Resource (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5619) 5619
vinblastine - pharmacology (3345) 3345
humans (3301) 3301
animals (2913) 2913
male (1672) 1672
female (1645) 1645
oncology (1645) 1645
vinblastine (1611) 1611
pharmacology & pharmacy (1116) 1116
mice (1073) 1073
vinblastine - analogs & derivatives (1035) 1035
vinblastine - administration & dosage (960) 960
colchicine - pharmacology (925) 925
middle aged (892) 892
rats (849) 849
adult (843) 843
antineoplastic combined chemotherapy protocols - therapeutic use (840) 840
aged (746) 746
chemotherapy (715) 715
antineoplastic agents - pharmacology (649) 649
cancer (617) 617
microtubules - drug effects (611) 611
p-glycoprotein (544) 544
antineoplastic agents, phytogenic - pharmacology (519) 519
dose-response relationship, drug (513) 513
biochemistry & molecular biology (498) 498
tumor cells, cultured (463) 463
cell line (460) 460
time factors (458) 458
vinblastine - therapeutic use (455) 455
vinorelbine (450) 450
antineoplastic combined chemotherapy protocols - adverse effects (415) 415
kinetics (412) 412
drug resistance (403) 403
cell line, tumor (401) 401
vinblastine - adverse effects (390) 390
vinblastine - metabolism (388) 388
expression (384) 384
vincristine - pharmacology (373) 373
treatment outcome (371) 371
cell biology (363) 363
cisplatin - administration & dosage (360) 360
cells, cultured (359) 359
tubulin - metabolism (356) 356
cisplatin (353) 353
in vitro techniques (328) 328
lung neoplasms - drug therapy (327) 327
doxorubicin (319) 319
doxorubicin - pharmacology (318) 318
microtubules (316) 316
cells (309) 309
paclitaxel - pharmacology (308) 308
microscopy, electron (302) 302
drug resistance, neoplasm (297) 297
microtubules - metabolism (292) 292
multidrug resistance (292) 292
vincristine (292) 292
cell division - drug effects (289) 289
breast neoplasms - drug therapy (280) 280
paclitaxel (279) 279
mitosis - drug effects (277) 277
vinblastine - pharmacokinetics (277) 277
apoptosis (272) 272
cell survival - drug effects (270) 270
doxorubicin - administration & dosage (269) 269
tubulin (268) 268
verapamil - pharmacology (266) 266
atp-binding cassette, sub-family b, member 1 - metabolism (257) 257
research (255) 255
cytochalasin b - pharmacology (250) 250
carcinoma, non-small-cell lung - drug therapy (245) 245
drug resistance, multiple (244) 244
multidrug-resistance (243) 243
adolescent (231) 231
abridged index medicus (228) 228
antineoplastic agents - therapeutic use (221) 221
drug synergism (220) 220
proteins (219) 219
therapy (218) 218
apoptosis - drug effects (217) 217
colchicine (217) 217
tritium (212) 212
drugs (208) 208
in-vitro (208) 208
drug administration schedule (207) 207
deoxycytidine - analogs & derivatives (205) 205
survival analysis (201) 201
antineoplastic combined chemotherapy protocols - administration & dosage (200) 200
aged, 80 and over (198) 198
carcinoma (191) 191
neoplasm staging (191) 191
pharmacology/toxicology (190) 190
bleomycin - administration & dosage (185) 185
hodgkin disease - drug therapy (185) 185
binding sites (184) 184
cricetinae (180) 180
medicine & public health (178) 178
antineoplastic agents (176) 176
pharmacokinetics (176) 176
microtubules - physiology (175) 175
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5827) 5827
French (61) 61
Russian (56) 56
Japanese (48) 48
German (43) 43
Italian (24) 24
Chinese (22) 22
Spanish (6) 6
Polish (4) 4
Hungarian (3) 3
Romanian (2) 2
Bulgarian (1) 1
Danish (1) 1
Dutch (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | TARGETED THERAPY | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | NUDE-MICE | TUMOR XENOGRAFTS | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | ANTITUMOR-ACTIVITY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects | Drug therapy | Medical treatment | Index Medicus
Journal Article
Oncogene, ISSN 0950-9232, 04/1999, Volume 18, Issue 13, pp. 2241 - 2251
Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To... 
Chemotherapy | Breast cancer | Synergy | Multiple drug effects analysis | HER-2/neu (c-erbB-2) | HER2/NEU-OVEREXPRESSING METASTATIC BREAST | synergy | GROWTH-FACTOR-RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTINEOPLASTIC AGENTS | breast cancer | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | SALIVARY-GLAND | chemotherapy | ENDOMETRIAL CANCER | CELL BIOLOGY | C-ERBB-2 PROTEIN | ONCOLOGY | multiple drug effects analysis | TUMOR NECROSIS FACTOR | GENETICS & HEREDITY | GENE-PRODUCT | Recombinant Proteins - therapeutic use | Doxorubicin - therapeutic use | Adenocarcinoma - pathology | Receptor, ErbB-2 - genetics | Humans | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vinblastine - therapeutic use | Topoisomerase II Inhibitors | Antimetabolites, Antineoplastic - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Receptor, ErbB-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | Etoposide - pharmacology | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Drug Synergism | Antimetabolites, Antineoplastic - therapeutic use | Adenocarcinoma - therapy | Antibiotics, Antineoplastic - therapeutic use | Mice, Nude | Cyclophosphamide - pharmacology | Immunization, Passive | Fluorouracil - pharmacology | Mice | Cell Cycle - drug effects | Trastuzumab | Neoplasm Transplantation | Paclitaxel - pharmacology | Antibiotics, Antineoplastic - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Transplantation, Heterologous | Fluorouracil - antagonists & inhibitors | Cyclophosphamide - therapeutic use | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Protein Processing, Post-Translational - drug effects | Female | Antineoplastic Agents - pharmacology | Thiotepa - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - biosynthesis | Etoposide - therapeutic use | Treatment Outcome | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Paclitaxel - therapeutic use | Neoplasms, Hormone-Dependent - therapy | Animals | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Vinblastine - pharmacology | Neoplasms, Hormone-Dependent - drug therapy | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Journal Article
Nature Cell Biology, ISSN 1465-7392, 03/2007, Volume 9, Issue 3, pp. 299 - 309
Non-muscle myosin II has diverse functions in cell contractility, cytokinesis and locomotion, but the specific contributions of its different isoforms have yet... 
ORGANIZATION | ADHESION | TRANSLOCATION | MIGRATING CELLS | CONTRACTILITY | CYTOSKELETON | RAC | DYNAMICS | MITOTIC KINESIN EG5 | INHIBITORS | CELL BIOLOGY | Nonmuscle Myosin Type IIA - antagonists & inhibitors | Embryonic Stem Cells - metabolism | RNA, Small Interfering - genetics | Embryonic Stem Cells - cytology | Humans | Nocodazole - pharmacology | Cercopithecus aethiops | Cell Movement - physiology | Heterocyclic Compounds, 4 or More Rings - pharmacology | Microtubules - metabolism | Nonmuscle Myosin Type IIB - antagonists & inhibitors | Transfection | Nonmuscle Myosin Type IIA - physiology | Guanine Nucleotide Exchange Factors - metabolism | Microtubules - drug effects | Nonmuscle Myosin Type IIA - genetics | Kinesin - genetics | Aminoquinolines - pharmacology | Kinesin - antagonists & inhibitors | T-Lymphoma Invasion and Metastasis-inducing Protein 1 | Nonmuscle Myosin Type IIB - physiology | Fibroblasts - metabolism | Guanine Nucleotide Exchange Factors - genetics | Nonmuscle Myosin Type IIB - genetics | Enzyme Inhibitors - pharmacology | Pyrimidines - pharmacology | Actomyosin - metabolism | Kinesin - metabolism | Naphthalenes - pharmacology | Azepines - pharmacology | Cell Movement - drug effects | Animals | Embryonic Stem Cells - drug effects | Cell Adhesion - physiology | Fibroblasts - drug effects | rac1 GTP-Binding Protein - antagonists & inhibitors | Fibroblasts - cytology | Mice | Vinblastine - pharmacology | Thiones - pharmacology | COS Cells | rac1 GTP-Binding Protein - metabolism | rac1 GTP-Binding Protein - genetics | Evaluation | Motility | Microtubules | Myosin | Physiological aspects | Genetic aspects | Properties | Health aspects | Cells | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2005, Volume 11, Issue 20, pp. 7508 - 7515
Purpose: BRCA2, FANCC , and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to... 
BRCA1, BRCA2 | Xenograft models | DNA damage and repair mechanisms | Pharmacogenetics/pharmacogenomics | Gastrointestinal cancers: other | GENE-MUTATIONS | LUNG-CANCER | FUNCTIONAL-ACTIVITY | ONCOLOGY | ABL TYROSINE KINASE | MITOMYCIN-C | PANCREATIC-CANCER | RANDOMIZED-TRIAL | PHASE-II | COMPLEMENTATION GROUP | CARCINOMA | Paclitaxel - pharmacology | Apoptosis - drug effects | Cross-Linking Reagents - pharmacology | Humans | Deoxycytidine - pharmacology | Chlorambucil - pharmacology | Fanconi Anemia Complementation Group C Protein - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Caspases - metabolism | Fanconi Anemia Complementation Group G Protein - genetics | Time Factors | Cross-Linking Reagents - therapeutic use | Fanconi Anemia Complementation Group G Protein - deficiency | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Cell Survival - drug effects | Fanconi Anemia Complementation Group Proteins - deficiency | Mitomycin - therapeutic use | Pancreatic Neoplasms - pathology | Fanconi Anemia Complementation Group Proteins - genetics | Etoposide - pharmacology | Pancreatic Neoplasms - genetics | Cisplatin - pharmacology | Xenograft Model Antitumor Assays - methods | Mitomycin - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Fanconi Anemia Complementation Group C Protein - deficiency | BRCA2 Protein - deficiency | Fluorouracil - pharmacology | Mice | Vinblastine - pharmacology | Mutation | Cell Cycle - drug effects | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2/2007, Volume 59, Issue 2, pp. 157 - 164
The inhibition of kinesin Eg5 by small molecules such as monastrol is currently evaluated as an approach to develop a novel class of antiproliferative drugs... 
Biomedicine | Chemosensitivity | Oncology | Cancer Research | Confocal microscopy | Human glioblastoma cells | Pharmacology/Toxicology | Kinesin inhibitors | Monastrol analogues | monastrol analogues | PROTEIN | P-GLYCOPROTEIN | PACLITAXEL | kinesin inhibitors | POTENT | ONCOLOGY | confocal microscopy | IN-VIVO | BIOLOGICAL EVALUATION | human glioblastoma cells | PHARMACOLOGY & PHARMACY | chemosensitivity | MULTIDRUG-RESISTANCE | BRAIN | Fluoresceins - pharmacology | Cysteine - analogs & derivatives | Flow Cytometry - methods | Paclitaxel - pharmacology | Tubulin Modulators - pharmacology | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Tubulin - metabolism | Spindle Apparatus - metabolism | Time Factors | Cysteine - pharmacology | Rotenone - pharmacology | Glioblastoma - metabolism | Molecular Structure | Kinesin - antagonists & inhibitors | Quinazolines - chemistry | Insecticides - pharmacology | Cell Survival - drug effects | Tetrahydroisoquinolines - pharmacology | Thiones - chemistry | Pyrimidines - pharmacology | Kinesin - metabolism | Acridines - pharmacology | Glioblastoma - pathology | Cell Line, Tumor | Cell Proliferation - drug effects | Spindle Apparatus - drug effects | Vinblastine - pharmacology | Thiones - pharmacology | Antineoplastic Agents, Phytogenic - pharmacology | Quinazolines - pharmacology | Brain tumors | Index Medicus
Journal Article
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 03/2008, Volume 75, Issue 6, pp. 1302 - 1312
Journal Article
Cell Cycle, ISSN 1538-4101, 05/2012, Volume 11, Issue 9, pp. 1851 - 1861
Journal Article
Molecular Cell, ISSN 1097-2765, 10/2017, Volume 68, Issue 1, pp. 210 - 223.e6
Chemical libraries paired with phenotypic screens can now readily identify compounds with therapeutic potential. A central limitation to exploiting these... 
CRISPRi | chemical genetics | genome-wide CRISPR screening | rigosertib | microtubules | CRISPRa | drug target identification | drug mechanism of action | PROTEIN | COLCHICINE | SMALL MOLECULES | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENOMIC ASSAYS | TARGETS | RISK MYELODYSPLASTIC SYNDROMES | TUBULIN | INHIBITOR | BINDING AGENTS | CELL BIOLOGY | Colchicine - pharmacology | Glycine - analogs & derivatives | Small Molecule Libraries - pharmacology | RNA, Guide - genetics | RNA, Guide - metabolism | Tubulin Modulators - pharmacology | Humans | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | Tubulin - genetics | Sulfones - pharmacology | Genetic Testing - methods | Recombinant Fusion Proteins - metabolism | Lentivirus - metabolism | Microtubules - metabolism | Tubulin - metabolism | Glycine - chemistry | Microtubules - drug effects | Sulfones - chemistry | Microtubules - ultrastructure | Kinesin - genetics | Lentivirus - genetics | Antineoplastic Agents - pharmacology | Tubulin - chemistry | Myelodysplastic Syndromes - metabolism | Tubulin Modulators - chemistry | Genetic Vectors - chemistry | Genetic Vectors - metabolism | Antineoplastic Agents - chemistry | Kinesin - metabolism | Glycine - pharmacology | CRISPR-Cas Systems | K562 Cells | Recombinant Fusion Proteins - genetics | Myelodysplastic Syndromes - genetics | Vinblastine - pharmacology | HeLa Cells | Mutation | Myelodysplastic Syndromes - pathology | Tubulins | Genomics | Genetic screening | Biochemical genetics | Cells | Index Medicus
Journal Article